The Tyrant Billionaire-Chapter 643 The Cleanup And Tying Loose Ends

Fukagawa's case wasn't the worst. He had mortgaged antiques, not his home. The truly unfortunate were those who had mortgaged the houses they lived in.

Their fate was likely eviction, homelessness, and a life on the streets.

After completing their stock redemption transactions, Japan's waters became dotted with floating bodies.

The Japanese government ordered the press to refrain from reporting on the matter.

...

At Hardy's estate, Sayuri knelt beside him, diligently massaging his shoulders. Her skills had improved significantly after professional training.

Recently, Sayuri had hosted a national singing competition, becoming Japan's most famous host. She was now preparing to star in a film.

Hardy, his eyes closed, murmured, "Once the film is completed, we'll release it in Japan and the West simultaneously. Then I'll make sure it's sent to the Oscars and wins Best Foreign Language Film. You'll become Japan's most celebrated actress."

Sayuri beamed with joy.

"Thank you, sir."

...

The Japanese financial crisis seemed to have reached its conclusion—or so it seemed—but unbeknownst to everyone, the capital behind these scandals had yet to tie up the loose ends. Just when everyone thought the storm had passed, a new development arose that shocked the world

Hans, the missing scientist, had reappeared.

The truth aboutHans Pharmaceuticalswas about to rewrite the narrative.

Everyone had been waiting to condemn Dr. Hans, but the investigation's conclusions were astonishingly unexpected.

"Can you confirm that Dr. Hans's new drug is effective?"

"Wasn't this a case of academic fraud and financial deception?"

"Could you provide more details?"

The reporters clamored with questions.

The spokesperson for the investigative team gestured for them to quiet down. Once the room calmed, he began explaining:

"First of all, the original report accusing Dr. Hans of fraud was published by theAmerican Financial Times. We later questioned the journalist who wrote the article. He admitted he had never been to Africa or interviewed Dr. Hans."

"As for the content of his article, he claimed it was based on information from a local African official, and that's what he used to write the report."

"The second report, which came from theNew York Times, was written by a correspondent stationed in Africa. That reporter interviewed officials involved in the second and third phases of clinical trials, as well as some trial participants."

"Those sources mentioned that Dr. Hans had administered a mixture of drugs to patients, including streptomycin. Without seeking clarification from Dr. Hans, the reporter prematurely concluded that he was committing fraud and published the story."

"We questioned Dr. Hans about this, and he clarified that the experiments in Africa were not purely for sales trials. He used a combination of medications to test both his new drug and the effects of mixed treatments on patients to determine the most effective therapy. His goal was to refine future treatment protocols."

"We reviewed the experimental data provided by Dr. Hans. The data showed that the new drug,Ethambutol, developed by Hans Pharmaceuticals, was indeed highly effective. It is more targeted against tuberculosis than broad-spectrum antibiotics like streptomycin and can genuinely be called a breakthrough drug."

Dr. Hans explained that since the African trials were not intended for rapid commercialization, and because the company had sufficient funding at the time, he conducted auxiliary experiments to speed up future trials in the U.S.

The reporters were stunned.

"Are you saying that theAmerican Financial Timesand theNew York Timesmisled their readers, causing the Hans Pharmaceuticals stock crash?"

"You could say that," the spokesperson nodded.

"Then where was Dr. Hans during all this? Why did he stay out of sight for over two months?" another reporter asked.

"He said he was exhausted from the experiments. He left some of the less critical, time-consuming tests to his assistants and took a vacation to spend time with his family," the spokesperson replied.

"What about the rumors that he sold off his shares? Why did he do that?"

The spokesperson shrugged. "That's a private matter, but since you're curious, I'll share what he told us. Hans Pharmaceuticals was deeply in debt at the time, and they hadn't yet developed a new drug. Another company offered to buy his shares and fund his continued research. Selling his shares was a perfectly logical decision."

"Perhaps due to the reduced stress, or maybe just sheer luck, Dr. Hans found some critical data in his earlier research shortly after receiving the funding. After several experiments, he successfully synthesizedEthambutol. Trials showed it had excellent efficacy against tuberculosis, which led to the subsequent developments."

Another reporter asked, "Does the new drug still require further trials? When will the Phase II trials in the U.S. begin?"

The spokesperson spread his hands. "That's beyond the scope of our investigation. My task was to determine if there was any financial fraud or deliberate deception in this case. I can responsibly tell you: Dr. Hans did not commit fraud."

"Alright, that concludes the press conference."

This news quickly made its way to the headlines.

The Hans Pharmaceuticals incident had been a hot topic, and people were finally learning that it had all been a misunderstanding.

TheAmerican Financial Timesand theNew York Timesfaced widespread criticism for their unverified reporting, which caused their reputations to take a significant hit.

However, This entire affair was orchestrated by Hardy, Andy, and Henry—a meticulously planned trap.

The Hans Pharmaceuticals debacle was a multi-layered scheme.

Of course, luck also played a role.

Initially, the plan was only to execute the first two phases: fleece the Japanese investors and exit. But by sheer fortune, Dr. Hans made an unexpected breakthrough during this time, successfully developingEthambutol.

Dr. Hans had initially intended to create a plausible drug as a facade—after all, as a respected scientist, he couldn't afford to produce something amateurish.

Surprisingly, his experiments led to a genuinely effective drug for tuberculosis. Upon learning this, Hardy, Andy, and Henry reworked their plan.

Throughout the operation, No laws were broken.

There was no fraud involved, just standard financial maneuvers. Even the sharpest detectives would find no evidence of wrongdoing.

As for theAmerican Financial Timesand theNew York Times,

New n𝙤vel chapters are published on freeweɓnøvel.com.

They were merely pawns.

TheAmerican Financial Times, a second-rate publication, eagerly published the story after receiving some carefully planted hints and data.

Stay updated through novelbuddy

For theNew York Times, Henry leveraged a sleeper agent—a business spy planted by their intelligence network. These agents didn't just gather information; they were also deployed to influence situations when necessary.

Hardy had been careful to keep theUniversal Timesentirely uninvolved, knowing that the reporting would eventually backfire.

With this third phase added to the plan, Hardy and Andy basically closed up any follow-up to this case and threw it back to the African officials andThe New York Times.

---